Part of The Weill Cornell Graduate School of Medical Sciences. A combined program of Weill Cornell Medical College and the Sloan-Kettering Institute,we are a premiere school in Biomedical Research. We are part of Cornell University (Ithaca, NY) but Weill Cornell Medical College is located in New York City. Read more about our programs of study:

The research activities of the Cornell Pharmacology Program faculty cover broad areas of modern pharmacological sciences. Faculty carry out research in cancer pharmacology, neuropharmacology, cardiovascular pharmacology, drug metabolism, toxicology, proteomics, molecular pharmacology, receptors and signal transduction, and drug design.

POSTDOCTORAL RESEARCH:

OPPORTUNITIES AND INFORMATION



PHOTOGRAPHS:

PARTIES AND EVENTS

SPRING RETREAT

GRADUATION

June 12, 2018
POSTDOCTORAL SEMINAR SERIES
Faten Taki, Ph.D.
Title: "Intergenerational programming of dominance via lactocrine signaling"
4:00PM - 4:30PM
Lecture Hall Room: A-250
Host: Dr. Miklos Toth


Henry Kelly, Ph.D.
Title: "A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer"
4:30PM - 5:00PM
Lecture Hall Room: A-250
Host: Dr. Jason Lewis


Text size:

April 26, 2018:

Dr. Yueming Li was chosen as the recipient of the Weill Cornell Graduate School Excellence in Teaching and Mentoring Award for the value of his teaching and mentoring of WCGS students. Dr. Li was nominated by, Drs. Derek Tan, David Scheinberg, Lisa Placanica and Natalya Gertsik and will be presented this award at the Weill Cornell Graduate School Convocation Ceremony on Wednesday, May 30th, at 10:00am in Uris Auditorium. Congratulations Dr. Li!

April 18, 2018:

Pathway to stop Diabetes Visionary Award Recipient.

Weill Cornell Faculty member, Dr. Samie R. Jaffrey has received the Pathway Visionary Award for his basic research project titled, "Rewiring Cellular Metabolic Networks in Diabetes." Dr. Jaffrey is developing a new type of gene therapy that will allow liver cells to "sense" metabolic abnormalities that occur in diabetes and then stimulate the production of proteins that would correct liver function.




April 12, 2018:

Scientists from the Giovanni Lorenzino Medical Foundation met with Weill Cornell faculty.

Pictured at lunch are: Lorraine Gudas, Emanuela Folco, David Hajjar, & Randi Silver. In the second picture are Roberto Levi, Guido Rasi, & Sergio Pecorelli. Dr. Rasi is the Executive Director of the European Medical Agency and he also gave a lecture titled: Role of Regulatory Agencies in the Development of Innovative Drugs.





April 4, 2018:

Tom Rossetti won the first year poster prize in the 38th annual Vincent du Vigneaud Research Symposium from his work in Dr. Kristen Pleil’s lab.

March 27, 2018:

Chuck Pratt, a graduate student in the lab of Dr. Grimm, has a new publication, titled: Nanoparticles as multimodal photon transducers of ionizing radiation, out in Nature Nanotechnology. Very nice research, Chuck!! To read more: click here

March 26, 2018:

Varun Chandrashekaran, Postdoctoral Associate in Pharmacology, Weill Cornell Medical College, has been awarded a 2-year fellowship from the Prevent Cancer Foundation. Dr. Chandrashekaran works in the laboratory of Dr. Lorraine Gudas.

Head and Neck Squamous Cell Carcinoma (HNSCC) is the seventh most common cancer worldwide. Surgery is the preferred treatment for early stage HNSCC. However, aggressive local invasion and metastasis lead to a high recurrence rate, which makes HNSCC a challenging disease to treat. To this end, prevention of HNSCC is an important goal.

The project builds on existing research that has shown that one type of retinoid (vitamin A derivative) drug can prevent tumor formation in a mouse model of this cancer. Dr. Chandrashekaran proposes that a combination of retinoids will have greater cancer preventive effect. Retinoids include vitamin A and related molecules. 13-Cis-RA, a retinoid, can reverse premalignant lesions and prevent the development of second primary tumors in head and neck cancers because of its ability to restore normal cell growth and differentiation. The lab uses a carcinogen to induce HNSCC tumors in mice, and has shown that the synthetic retinoid CD1530 effectively prevents the development of oral tumors in the mice. AC261066 is another synthetic retinoid drug that has been identified in the laboratory. AC261066 may also have cancer preventive effects in HNSCC because its target protein is a purported tumor suppressor. Dr. Chandrashekaran’s hypothesis is that AC261066, in combination with CD1530, will prevent the induced HNSCC tumor formation with greater efficacy than either drug alone. Collectively, this research has the potential to identify new strategies for more effective retinoid-based cancer prevention in HNSCC. These findings should save lives by preventing cancer in high-risk individuals.


March 15, 2018:

Dr. Norman (Ned) Sharpless, the new Director of the NCI, gave an inspiring talk at Weill Cornell Medicine. He discussed new treatment strategies, funding of the NCI, and a variety of other related topics.


January 11, 2018:

The first lecture, given by Dr. Ignacio Rodriguez, of the “From Molecule to Prescription” Drug Development PhD course was outstanding. Here is a picture of the class. Postdocs and faculty are most welcome to sit in on lectures! For a link to the syllabus, click here: click here


ALUMNI NEWS (Est. 10/2015):

CLICK HERE

March 21, 2018:

Jeanne Farrell, who received her PhD in our Weill Cornell Pharmacology Program (advisors Drs. Buck and Levin), was just promoted to the position of Associate Vice President, Office of Technology Transfer, The Rockefeller University. Congratulations, Jeanne!!


December, 2017:

Lorraine Gudas connected with Sara DiNapoli, Julia Silveira, & Emily Mercer at a holiday party!. Emily (PhD awarded last year in Pharmacology) is now working at the healthcare co. IQVIA in NYC.